Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC
MADRID — Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) doubled when patients received a radionuclide ligand targeting prostate-specific membrane antigen (PSMA) instead of switching to another androgen receptor pathway inhibitor (ARPI), a randomized trial showed. In patients with prior progression on an ARPI, median rPFS increased from 5.9 months with another ARPI […]
Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?
Come December, as I observe my “pros-mitzvah” — 13 years on active surveillance (AS) for very low-risk prostate cancer — I feel I’m at a tipping point. Should I stay the course and keep monitoring my lesion — a single Gleason 6 of less than 1 mm seen back in 2010 and never again in […]
Prostate Cancer Is Not Just an ‘Old Man’s Disease’
Gabe Canales’ experience with low-risk prostate cancer nearly matches mine — with a couple of caveats, including a 27-year difference in the ages at which we were both diagnosed. I was 62 years old with a rising prostate-specific antigen (PSA) level, close to the average age of diagnosis. Canales was just 35. Canales, author of […]
MR-Guided Adaptive SBRT Tied to Reduced Side Effects in Prostate Cancer
Magnetic resonance (MR)‐guided adaptive stereotactic body radiotherapy (SBRT) for prostate cancer was associated with significantly lower rates of acute genitourinary and gastrointestinal toxicities compared with CT-guided non-adaptive SBRT, according to a systematic review and meta-analysis. Across 29 prospective studies involving over 2,500 patients, the risk of short‐term genitourinary side effects was reduced by 44% with […]
Certain Toxic Effects Higher With Newer Prostate Cancer Therapies
Second-generation anti-androgens (AAs) for the treatment of prostate cancer are associated with an increased risk of cognitive and functional toxic effects, according to results from a systematic review and meta-analysis. Across 12 randomized trials involving over 13,000 patients, increased risks of cognitive toxic effects (risk ratio [RR] 2.10, 95% CI 1.30-3.38, P=0.002) and fatigue (RR […]
FDA Staff Not Sold on Broad Olaparib Indication in Metastatic CRPC
Olaparib (Lynparza) plus abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) is only clearly effective in patients with BRCA mutations, FDA staff contended in a briefing document released ahead of an advisory committee meeting. On Friday, the FDA is asking its Oncologic Drugs Advisory Committee (ODAC) to weigh in on whether a […]
Older Men Still Overscreened for Prostate Cancer, Survey Says
Older men are being overscreened for prostate cancer, despite U.S. Preventive Services Task Force (USPSTF) guidelines against prostate-specific antigen (PSA) testing in men ages 70 and up, a survey study showed. Among a cohort of over 30,000 men, recent PSA screening rates were 55.3% for men ages 70 to 74, 52.1% for those ages 75 […]
Fresh produce contaminated with toxic BPA-like chemicals found in food labels: BPA is banned in some countries but similar chemicals like BPS are still allowed
Steps were taken in Canada to reduce the use of Bisphenol A (BPA), a toxic chemical linked to prostate and breast cancer, commonly found in plastics, the lining of food cans, water bottles, and paper receipts. But in many cases, it has been replaced with similar hormone disrupting chemicals, like Bisphenol S (BPS). A new […]
Deaths From PSA-Detected Prostate Cancer Low at 15 Years, No Matter the Treatment
For prostate cancers detected by screening, cancer-specific mortality was low at 15-year follow-up regardless of whether patients underwent active monitoring, prostatectomy, or radiotherapy, results from the phase III randomized ProtecT study showed. Among over 1,600 men from the U.K. with prostate cancers detected by a prostate-specific antigen (PSA) test, death from their malignancy occurred in […]
Use of Active Surveillance in Prostate Cancer on the Rise, but Highly Variable
While use of active surveillance for the management of low-risk prostate cancer has increased in the U.S., it still varies widely both at the practitioner level and even within urology practices, according to a cohort study. Looking at over 20,000 patients included in a quality reporting registry, the rate of active surveillance increased “sharply and […]